Skip to main content

ERRATUM article

Front. Oncol., 04 January 2023
Sec. Pediatric Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1124071
This article is part of the Research Topic Liquid Biopsies in Pediatric Oncology View all 9 articles

Erratum: Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: A proof of concept study

This article is an erratum on:

  1. Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: A proof-of-concept study

by Arthur C, Rezayee F, Mogensen N, Saft L, Rosenquist R, Nordenskjöld M, Harila-Saari A, Tham E and Barbany G (2022) 12:899325. doi: 10.3389/fonc.2022.899325

Due to a production error, there was a mistake in Figure 6 as published. The part labels in the figure were not placed correctly. The corrected Figure 6 appears below. The publisher apologizes for this mistake.

FIGURE 6
www.frontiersin.org

Figure 6 (A–D) Kinetics of leukemic targets in CSF and plasma by ddPCR during treatment. (A) CSF and (B) plasma results in patient 3. (C) CSF and (D) plasma results in patient 4. Empty symbols denote trace values (1–2 positive droplets). CSF, cerebrospinal fluid; ddPCR, droplet digital PCR.

The original version of this article has been updated.

Keywords: acute lymphoblastic leukemia, liquid biopsy, disease monitoring, precision medicine, whole-genome sequencing, structural variation, technical feasibility, diagnostic performance

Citation: Frontiers Production Office (2023) Erratum: Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: A proof of concept study. Front. Oncol. 12:1124071. doi: 10.3389/fonc.2022.1124071

Received: 14 December 2022; Accepted: 14 December 2022;
Published: 04 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.